Spyre Therapeutics Funding & Investors
San Francisco, CA
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.
spyre.comTotal Amount Raised: $826,000,000
Spyre Therapeutics Funding Rounds
Post Ipo Equity
$200,000,000
Post Ipo Equity
$180,000,000
Post Ipo Equity Investors
Perceptive AdvisorsBoxer CapitalDeep Track CapitalAdage Capital ManagementFarallon Capital ManagementLogos CapitalAvidity PartnersRTW InvestmentsDarwin GlobalPost Ipo Equity
$180,000,000
Post Ipo Equity Investors
Affinity Asset AdvisorsGreat Point CapitalBoxer CapitalCommodore CapitalDeep Track CapitalWoodline PartnersAccess IndustriesCormorant Asset ManagementVenrock Healthcare Capital PartnersRTW InvestmentsPerceptive AdvisorsFairmount Funds ManagementBraidwellPolar CapitalPost Ipo Equity
$210,000,000
IPO
Unknown
Series B
$44,000,000
Series B Investors
Lilly VenturesNovartis Venture FundNew Ground VenturesUT Horizon FundRA Capital ManagementCowenVenrockOrbiMed AdvisorsAlly Bridge GroupJennison AssociatesRock Springs CapitalSeries A
$12,000,000
Series A Investors
Lilly VenturesKBI BiopharmaNovartis Venture FundUT Horizon Fund
Funding info provided by Diffbot.